The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Role of Immunotherapy in Triple-Negative Breast Cancer
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has several key characteristics that enhance ICI responses. Strategies to improve anticancer immune responses in TNBC are urgently needed to extend survival for patients with metastatic disease. This review presents ICI monotherapy response rates and discusses combination strategies with chemotherapy, targeted therapies, and novel immunotherapies. It concludes with a summary of immunotherapy biomarkers in TNBC and a call to action for future directions of research critical to advancing the efficacy of immunotherapy for patients with TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 989
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.-C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 773
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Self-citationRimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 695
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Kulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D., MS, M. J., Shah, S., Hanks, D., Wang, J., et al. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0043-oa · Cited by 536
Gatalica, Z., Snyder, C., Maney, T., Ghazalpour, A., Holterman, D. A., Xiao, N., Overberg, P., Rose, I., Basu, G. D., Vranic, S., et al. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0654 · Cited by 522
George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 483
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454
Self-citationTchou, J., Zhao, Y., Levine, B. L., Zhang, P. J., Davis, M. M., Melenhorst, J. J., Kulikovskaya, I., Brennan, A. L., Liu, X., Lacey, S. F., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0189 · Cited by 452
Charych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., Sheng, D., Liu, X., Sims, P. W., VanderVeen, L. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1631 · Cited by 398
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Barroso-Sousa, R., Jain, E., Cohen, O., Kim, D., Buendia-Buendia, J., Winer, E., Lin, N., Tolaney, S. M., & Wagle, N. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.010 · Cited by 362
Self-citationCrompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R. L., Tran, E., Hanada, K.-I., Yu, Z., Palmer, D. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 345
Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E. V., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0280 · Cited by 337
What does PD-L1 positive or negative mean?
Ribas, A., & Hu-Lieskovan, S. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161462 · Cited by 335
Adams, S., Diamond, J. R., Hamilton, E., Pohlmann, P. R., Tolaney, S. M., Chang, C.-W., Zhang, W., Iizuka, K., Foster, P. G., Molinero, L., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5152 · Cited by 288
Self-citationThe genomic landscape of breast cancer and its interaction with host immunity
Luen, S., Virassamy, B., Savas, P., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 277
(2019) · doi:10.1158/2159-8290.cd-18-1495 · Cited by 231
Applications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 205
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Antón, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-gs3-04 · Cited by 136
Cortés, J., Lipatov, O. N., Im, S., Gonçalvès, A., Lee, K. S., Schmid, P., Tamura, K., Testa, L., Witzel, I., Ohtani, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.010 · Cited by 131
Schmid, P., Cruz, C., Braiteh, F. S., Eder, J. P., Tolaney, S. M., Kuter, I., Nanda, R., Chung, C. T., Cassier, P. A., Delord, J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2986 · Cited by 119
Self-citationRugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.009 · Cited by 116
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Kraya, A., Maxwell, K. N., Wubbenhorst, B. S., Wenz, B. M., Pluta, J. B., Rech, A. J., Dorfman, L. M., Lunceford, N., Barrett, A., Mitra, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0468 · Cited by 109
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
Kalli, K. R., Block, M. S., Kasi, P. M., Erskine, C. L., Hobday, T. J., Dietz, A. B., Padley, D. J., Gustafson, M. P., Shreeder, B., Puglisi-Knutson, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2499 · Cited by 104
Ueda, S., Saeki, T., Takeuchi, H., Shigekawa, T., Yamane, T., Kuji, I., & Osaki, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.122 · Cited by 99
Emens, L., Loi, S., Rugo, H. S., Schneeweiß, A., Dieras, V. C., Iwata, H., Barrios, C., Nechaeva, M. N., Molinero, L. L., Duc, A. N., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-gs1-04 · Cited by 81
Schmid, P., Cortés, J., Dent, R. A., Pusztai, L., McArthur, H. L., Küemmel, S., Bergh, J. C. S., Denkert, C., Park, Y. H., Hui, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.003 · Cited by 76
Tolaney, S. M., Kalinsky, K. M., Kaklamani, V., Savulsky, C. I., Olivo, M. S., Aktan, G., Kaufman, P. A., Xing, D., Almonte, A., Misir, S., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd6-13 · Cited by 72
Self-citationSchmid, P., Adams, S., Rugo, H. S., Schneeweiß, A., Barrios, C. H., Iwata, H., Dieras, V. C., Henschel, V., Molinero, L. L., Chui, S. Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1003 · Cited by 71
Loi, S., Winer, E. P., Lipatov, O. N., Im, S., Gonçalvès, A., Cortés, J., Lee, K. S., Schmid, P., Testa, L., Witzel, I., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-pd5-03 · Cited by 68
Cancer vaccines: translation from mice to human clinical trials
Maeng, H. M., Terabe, M., & Berzofsky, J. A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.001 · Cited by 56
Diab, A. K., Hurwitz, M. E., Cho, D. C., Papadimitrakopoulou, V. A., Curti, B. D., Tykodi, S. S., Puzanov, I. J., Ibrahim, N. K., Tolaney, S. M., Tripathy, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3006 · Cited by 56
Self-citationSchmid, P., Loirat, D., Savas, P. S., Espinosa, E., Boni, V., Italiano, A., White, S. C., Singel, S. M., Withana, N. P., Mani, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct049 · Cited by 47
Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.
Barroso‐Sousa, R., Jain, E., Kim, D., Partridge, A. H., Cohen, O., & Wagle, N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1010 · Cited by 14
Senkus, E., Domchek, S. M., Im, S., Xu, B., Armstrong, A. C., Masuda, N., Delaloge, S., Li, W., Tung, N., Conte, P., et al. (2018) · European Journal of Cancer · doi:10.1016/s0959-8049(18)30285-5 · Cited by 13
Cited by
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Famta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01669-9 · Cited by 21
Metadata
- Authors
- Keenan, T. E., & Tolaney, S. M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2020-04
- Volume
- 18
- Issue
- 4
- Pages
- 479-489
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3014160477
- Cited by
- 606
- References
- 75
- FWCI
- 26.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.